Integra Lifesciences Hldgs Cp Stock Price, News & Analysis

Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported first quarter 2023 revenues of $380.8 million, marking a 1.1% increase year-over-year on a reported basis and 4.6% growth organically. GAAP earnings per diluted share were $0.29, down from $0.39 in the previous year, with adjusted earnings remaining steady at $0.74. The company reaffirmed its full-year revenue guidance of $1,602 to $1,620 million and adjusted EPS guidance of $3.43 to $3.51. Segment performance showed $248.1 million in revenues from Codman Specialty Surgical, while Tissue Technologies generated $132.7 million. Key highlights include strong demand across product lines and a successful launch of new products. The company also strengthened its balance sheet and returned value to shareholders through a $150 million share repurchase program.

Integra LifeSciences Holdings Corporation (NASDAQ: IART) will announce its first quarter 2023 financial results on April 26, 2023, before market opening. A conference call will follow at 8:30 a.m. ET to discuss the earnings.

Investors can access the live webcast on the company's investor website. A replay of the call will be available afterward. Integra is renowned for its regenerative tissue technologies and neurosurgical solutions, providing high-quality products that support optimal patient care.

Integra LifeSciences Holdings Corporation (NASDAQ: IART) reported its 2022 financial results, revealing fourth quarter revenues of $398.0 million, a 1.8% decrease year-over-year, but a 2.9% organic growth. GAAP earnings per diluted share rose to $0.63 from $0.53 in Q4 2021. For the full year, revenues reached $1,557.7 million, a 1.0% increase, with GAAP EPS at $2.16. The company provided guidance for 2023, expecting revenues of $1,602 million to $1,620 million and adjusted EPS between $3.43 and $3.51, indicating optimism for growth as markets recover from COVID-19 impacts.

Integra LifeSciences Holdings Corporation (NASDAQ: IART) will announce its fourth quarter 2022 financial results on February 22, 2023, before the market opens. A conference call with the management team is scheduled for 8:30 a.m. ET on the same day. This event will be accessible via a live webcast on the company's investor website. Integra is recognized as a leader in regenerative tissue technologies and neurosurgical solutions, providing a wide range of high-quality products to enhance patient care. Investors can find further details and register for the call on their official site.

Campbell Soup Company (NYSE:CPB) announced the appointment of Carrie L. Anderson as Executive Vice President and Chief Financial Officer, effective February 6. Anderson will oversee the finance function including controllership, corporate financial planning, and analysis, among other areas. She succeeds Mick Beekhuizen, who transitioned to President of the Meals & Beverages division. Anderson joins from Integra LifeSciences where she served as CFO since 2019. With a background in diverse industries and a strong financial acumen, her leadership is expected to enhance Campbell's growth and performance.

Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced preliminary financial results for the fourth quarter and full-year 2022, revealing expected revenues of $397-$398 million for Q4, a 2% decrease reported but a 3% organic increase year-over-year. For the full year, revenues are projected at $1,557-$1,558 million, reflecting a 1% reported increase and 4% organic growth. Adjusted earnings per diluted share for both periods are expected to exceed prior guidance. The company also plans a $150 million share repurchase program in 2023 and will present at the J.P. Morgan Healthcare Conference on January 11.

Integra LifeSciences (NASDAQ: IART) announced that its CEO, Jan De Witte, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 7:30 PM ET. A live webcast will be accessible through Integra's investor relations website. The company, recognized for its regenerative tissue technologies and neurosurgical solutions, aims to support clinicians in delivering optimal patient care. Integra boasts a robust portfolio of high-quality brands.